Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma. The company has a strategic collaboration and license agreement with GSK to research, develop, and commercialize NY-ESO T-cell therapy. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone44-12-3543-0000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$59.51 million
Profitability
Miscellaneous
Employees406
Next Earnings Date8/1/2019 (Estimated)
OptionableOptionable
Adaptimmune Therapeutics (NASDAQ:ADAP) Frequently Asked Questions
What is Adaptimmune Therapeutics' stock symbol?
Adaptimmune Therapeutics trades on the NASDAQ under the ticker symbol "ADAP."
How were Adaptimmune Therapeutics' earnings last quarter?
Adaptimmune Therapeutics PLC - (NASDAQ:ADAP) announced its quarterly earnings results on Monday, May, 6th. The biotechnology company reported ($0.24) EPS for the quarter, topping analysts' consensus estimates of ($0.28) by $0.04. Adaptimmune Therapeutics had a negative net margin of 161.09% and a negative return on equity of 45.03%. View Adaptimmune Therapeutics' Earnings History.
When is Adaptimmune Therapeutics' next earnings date?
What price target have analysts set for ADAP?
6 equities research analysts have issued 12-month target prices for Adaptimmune Therapeutics' shares. Their forecasts range from $4.15 to $12.00. On average, they anticipate Adaptimmune Therapeutics' share price to reach $6.7875 in the next year. This suggests a possible upside of 84.9% from the stock's current price. View Analyst Price Targets for Adaptimmune Therapeutics.
What is the consensus analysts' recommendation for Adaptimmune Therapeutics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adaptimmune Therapeutics in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Adaptimmune Therapeutics.
Has Adaptimmune Therapeutics been receiving favorable news coverage?
News stories about ADAP stock have been trending negative this week, InfoTrie Sentiment reports. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Adaptimmune Therapeutics earned a news impact score of -2.0 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 8.0 out of 10, indicating that recent news coverage is very likely to have an effect on the stock's share price in the near future.
Who are some of Adaptimmune Therapeutics' key competitors?
Some companies that are related to Adaptimmune Therapeutics include Coherus Biosciences (CHRS), Rubius Therapeutics (RUBY), Alector (ALEC), Fate Therapeutics (FATE), Momenta Pharmaceuticals (MNTA), Sangamo Therapeutics (SGMO), Atara Biotherapeutics (ATRA), Editas Medicine (EDIT), NanoString Technologies (NSTG), GENFIT S A/ADR (GNFT), Voyager Therapeutics (VYGR), Autolus Therapeutics (AUTL), MeiraGTx (MGTX), BAVARIAN NORDIC/S (BVNRY) and Twist Bioscience (TWST).
What other stocks do shareholders of Adaptimmune Therapeutics own?
Who are Adaptimmune Therapeutics' key executives?
Adaptimmune Therapeutics' management team includes the folowing people:
- Mr. James Julian Noble, CEO & Director (Age 60)
- Dr. Helen Katrina Tayton-Martin, Co-Founder & Chief Bus. Officer (Age 52)
- Mr. Adrian Rawcliffe, Chief Financial Officer (Age 47)
- Mr. William C. Bertrand Jr., Chief Operating Officer (Age 54)
- Dr. Rafael Amado, Pres of R&D (Age 55)
When did Adaptimmune Therapeutics IPO?
(ADAP) raised $150 million in an initial public offering (IPO) on Wednesday, May 6th 2015. The company issued 9,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners acted as the underwriters for the IPO and Guggenheim Securities was co-manager.
Who are Adaptimmune Therapeutics' major shareholders?
Adaptimmune Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (3.67%), Man Group plc (1.28%), BlackRock Inc. (0.79%), Renaissance Technologies LLC (0.76%), JPMorgan Chase & Co. (0.38%) and Rathbone Brothers plc (0.27%). Company insiders that own Adaptimmune Therapeutics stock include Adrian Rawcliffe, Ali Behbahani, David M Mott, Enterprise Associates 14 New, Gwendolyn Knowlt Binder-Scholl, Lawrence M Alleva, Orbimed Advisors Llc, Peter A Thompson, Rafael Amado, Ravi Viswanathan and William C Bertrand, Jr. View Institutional Ownership Trends for Adaptimmune Therapeutics.
Which institutional investors are selling Adaptimmune Therapeutics stock?
ADAP stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., BlackRock Inc., WS Management Lllp, Creative Planning, DekaBank Deutsche Girozentrale and Acadian Asset Management LLC. Company insiders that have sold Adaptimmune Therapeutics company stock in the last year include Adrian Rawcliffe, Gwendolyn Knowlt Binder-Scholl, Orbimed Advisors Llc, Peter A Thompson, Rafael Amado and William C Bertrand, Jr. View Insider Buying and Selling for Adaptimmune Therapeutics.
Which institutional investors are buying Adaptimmune Therapeutics stock?
ADAP stock was bought by a variety of institutional investors in the last quarter, including Man Group plc, Morgan Stanley, Renaissance Technologies LLC, Baillie Gifford & Co., Rathbone Brothers plc, Raymond James & Associates, Oxford Asset Management LLP and Mitsubishi UFJ Kokusai Asset Management Co. Ltd.. Company insiders that have bought Adaptimmune Therapeutics stock in the last two years include Ali Behbahani, David M Mott, Enterprise Associates 14 New, Lawrence M Alleva and Ravi Viswanathan. View Insider Buying and Selling for Adaptimmune Therapeutics.
How do I buy shares of Adaptimmune Therapeutics?
Shares of ADAP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Adaptimmune Therapeutics' stock price today?
One share of ADAP stock can currently be purchased for approximately $3.67.
How big of a company is Adaptimmune Therapeutics?
Adaptimmune Therapeutics has a market capitalization of $384.22 million and generates $59.51 million in revenue each year. The biotechnology company earns $-95,510,000.00 in net income (profit) each year or ($0.96) on an earnings per share basis. Adaptimmune Therapeutics employs 406 workers across the globe.
What is Adaptimmune Therapeutics' official website?
How can I contact Adaptimmune Therapeutics?
Adaptimmune Therapeutics' mailing address is 60 JUBILEE AVENUE MILTON PARK OXFORDSHIRE, ABINGDON X0, OX14 4RX. The biotechnology company can be reached via phone at 44-12-3543-0000 or via email at [email protected]
MarketBeat Community Rating for Adaptimmune Therapeutics (NASDAQ ADAP)
MarketBeat's community ratings are surveys of what our community members think about Adaptimmune Therapeutics and other stocks. Vote "Outperform" if you believe ADAP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADAP will underperform the S&P 500 over the long term. You may vote once every thirty days.
